Pelthos Therapeutics Inc. Earnings Per Share (Basic)
Pelthos Therapeutics Inc. (PTHS) reported Earnings Per Share (Basic) of -$6.62 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Pelthos Therapeutics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$6.62.
- Pelthos Therapeutics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$7.57.
- Pelthos Therapeutics Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$6.81.
- Pelthos Therapeutics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$5.30.
- Pelthos Therapeutics Inc. earnings per share, basic for fiscal 2025 was -$23.04.
- Pelthos Therapeutics Inc. earnings per share, basic for fiscal 2024 was -$14.27.
- Pelthos Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$5.78, a 202.30% decline from fiscal 2022.
- Pelthos Therapeutics Inc. earnings per share, basic for fiscal 2022 was $5.65.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.62 10-Q · filed 2026-08-13 | -$14.15 10-Q · filed 2026-08-13 | -$20.98 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$26.39 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$7.57 10-Q/A · filed 2026-08-13 | -$3.09 10-Q · filed 2026-05-14 | -$14.40 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$19.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$26.04 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2025-12-31 | -$6.81 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$12.15 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$18.00 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$23.04 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$5.30 10-Q · filed 2025-11-13 | -$10.60 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$14.96 10-Q · filed 2025-11-13 | -$19.13 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$5.29 10-Q · filed 2026-08-13 | -$5.38 10-Q · filed 2025-08-13 | -$8.56 10-Q · filed 2026-08-13 | -$8.64 10-Q · filed 2025-08-13 | -$11.79 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$14.77 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-03-31 | -$3.21 10-Q/A · filed 2026-08-13 | -$0.32 10-Q · filed 2025-05-13 | -$6.40 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.34 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$12.41 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2024-12-31 | -$3.19 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$6.12 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$9.19 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$14.27 10-K · filed 2026-03-19 | -$1.43 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$2.93 10-Q · filed 2025-11-13 | -$0.29 10-Q · filed 2024-11-13 | -$6.00 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$11.12 10-Q · filed 2025-11-13 | -$1.11 10-Q · filed 2024-11-13 | -$5.13 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-06-30 | -$3.07 10-Q · filed 2025-08-13 | -$0.31 10-Q · filed 2024-08-13 | -$8.28 10-Q · filed 2025-08-13 | -$0.83 10-Q · filed 2024-08-13 | -$3.45 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$4.74 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-03-31 | -$0.55 10-Q · filed 2025-05-13 | -$1.97 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$3.13 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$4.13 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||||
| 2023-12-31 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$3.65 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$4.81 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$5.78 10-K · filed 2025-03-27 | $5.78 10-K · filed 2024-04-16 | |||
| 2023-09-30 | -$1.44 10-Q · filed 2024-11-13 | -$2.39 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$3.24 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | -$0.95 10-Q · filed 2024-08-13 | -$1.82 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$0.87 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | $5.65 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |